Trisulfide HGF Enhancers for Stronger c-Met Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods do not effectively enhance the physiological activity of hepatocyte growth factor (HGF) for therapeutic applications.

Innovation Solution

Trisulfide compounds, such as glutathione trisulfide and lipoic acid trisulfide, enhance the binding between HGF and its receptor c-Met, thereby increasing HGF's cell proliferation action in a concentration-dependent manner.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If HGF is used for therapeutic applications, then tissue and organ regeneration is promoted, but the physiological activity is insufficient without enhancement

Engineering Contradiction:
Improvephysiological activity of HGFVSAvoidcell proliferation action
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent introduces trisulfide compounds as intermediary substances that mediate between HGF and its receptor c-Met. These compounds enhance the binding affinity and signaling efficiency, thereby improving physiological activity without directly acting as the therapeutic agent itself

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the chemical environment by introducing trisulfide compounds that change the binding parameters between HGF and c-Met. This increases the affinity and efficiency of the HGF-c-Met interaction, leading to enhanced cell proliferation and physiological effects

Inventive Principle:
Principle #35Parameter changes

2Reliability

If trisulfide compounds are added to enhance HGF activity, then binding between HGF and c-Met is improved, but the complexity of the therapeutic formulation increases

Engineering Contradiction:
Improvebinding affinity of HGF-c-MetVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The trisulfide compounds serve as simple intermediary molecules that can be easily incorporated into therapeutic formulations. Their small molecular size and ability to function as binding enhancers make them practical additions without requiring complex formulation systems

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The trisulfide compounds have multiple functions: they enhance binding affinity, improve signaling efficiency, and can be used across different therapeutic applications of HGF. This multi-functionality reduces the need for multiple separate agents, simplifying the overall formulation

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The trisulfide compounds significantly boost the physiological activity of HGF, including its cell proliferation-promoting effects on various cell types and potential neuroprotective actions.

Implementation Method 1

trisulfide compounds enhance the binding between HGF and its receptor c-Met

Methodology Applied
Scientific EffectChemical Bonding: Chemical Bonding

Data Source

PatentEP4647072A1Enhancer of physiological activity of hepatocyte growth factor
Publication Date: 2025.11.12 KYOWA HAKKO BIO CO LTD
  • EP4647072A1 patent drawingFigure 1(A)~1(C)
  • EP4647072A1 patent drawingFigure 2(A)~2(B)
  • EP4647072A1 patent drawingFigure 3a~3d

AI summary

Disclosed is an enhancer of the physiological activity of a hepatocyte growth factor, the enhancer comprising a trisulfide compound. The trisulfide compound comprises at least one component selected from the group consisting of glutathione trisulfide, a pharmaceutically acceptable salt of glutathione trisulfide, a compound represented by formula (1), a pharmaceutically acceptable salt of the compound, a cyclodextrin inclusion complex of the compound or the pharmaceutically acceptable salt, a compound represented by formula (6), a pharmaceutically acceptable salt of the compound, and a cyclodextrin inclusion complex of the compound or the pharmaceutically acceptable salt.